Full Press Release Details
TARRYTOWN, N.Y.,Dec. 3, 2021/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is scheduled to participate in a virtual fireside chat at the H.C. Wainwright & Co. event – Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and Alnylam's RNAi Platform Collaboration Update – at 2:00 p.m. ET onMonday, December 6, 2021.
Aris Baras, M.D., Senior Vice President at Regeneron and Head of the Regeneron Genetics Center, will participate on behalf of Regeneron.
The session may be accessed from the "Investors & Media" page of Regeneron's website athttps://investor.regeneron.com/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days.
About RegeneronRegeneron (NASDAQ:REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietaryVelociSuite®technologies, such asVelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visitwww.regeneron.comor follow @Regeneron on Twitter.